NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- LEXEO Therapeutics Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors.

2024年7月8日，纽约（环球通讯社）--临床阶段基因医学公司LEXEO Therapeutics Inc.（纳斯达克：LXEO）今天宣布任命argenx SE联合创始人兼首席执行官Tim Van Hauwermeiren为董事会独立非执行董事。

Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries.  .

Van Hauwermeiren先生是一位经验丰富的生物技术高管，在生命科学和消费品行业的一般管理和业务发展方面拥有20多年的经验。。

“Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe’s most successful biotech companies, and I am thrilled to welcome him to our Board of Directors,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “Tim’s deep and relevant experience in company building from clinical to commercial stage will be an invaluable asset to Lexeo as we embark on our next phase of growth and progress our pipeline into later stages of clinical and commercial development.”.

Lexeo Therapeutics首席执行官R.Nolan Townsend表示：“蒂姆是一位成就斐然的生命科学企业家，创建了欧洲最成功的生物技术公司之一，我很高兴欢迎他加入我们的董事会。”。“Tim在从临床到商业阶段的公司建设方面的丰富经验将成为Lexeo的宝贵资产，因为我们将进入下一个增长阶段，并将我们的管道推进临床和商业发展的后期阶段。”。

Mr. Van Hauwermeiren is co-founder, CEO and a Board Member of argenx, a global immunology company valued at almost $25 billion focused on severe autoimmune diseases. During his 15-year tenure, he has overseen the development and launch of the company’s first commercial product, efgartigimod, for the treatment of multiple severe autoimmune diseases, and he has expanded the company’s footprint across Europe, the U.S.

Van Hauwermeiren先生是argenx的联合创始人、首席执行官和董事会成员，argenx是一家专注于严重自身免疫性疾病的全球免疫学公司，价值近250亿美元。在他15年的任期内，他监督了该公司第一个用于治疗多种严重自身免疫性疾病的商业产品efgartigimod的开发和推出，并将该公司的足迹扩展到了欧洲、美国。

and Asia. Additionally during his time at argenx, Mr. Van Hauwermeiren has secured more than $4 billion in funding through equity raises and business development transactions with major pharmaceutical companies. Prior to argenx, Mr. Van Hauwermeiren held roles with increasing levels of responsibility at Ablynx and Procter & Gamble..

和亚洲。此外，在argenx任职期间，Van Hauwermeiren先生通过与主要制药公司的股权融资和业务发展交易，获得了40多亿美元的资金。在加入argenx之前，Van Hauwermeiren先生在Ablynx和宝洁公司担任越来越重要的角色。。

“I am honored to join Lexeo’s Board at this important stage in the company’s growth,” said Mr. Van Hauwermeiren. “I am impressed by the company’s innovative science, pipeline and bold thinking, and I look forward to sharing my experiences and learnings with the management team as we work to bring life-changing therapies to patients with devastating genetic diseases.”.

Van Hauwermeiren先生说：“在公司发展的这个重要阶段，我很荣幸加入Lexeo的董事会。”。“公司创新的科学、管道和大胆的思维给我留下了深刻的印象，我期待着与管理团队分享我的经验和教训，因为我们正在努力为患有毁灭性遗传疾病的患者带来改变生命的疗法。”。

Mr. Van Hauwermeiren also serves on the Board of Directors of iTeos Pharmaceuticals, and previously served on the Board of Directors of RayzeBio prior to the company’s acquisition by Bristol Myers Squibb. He holds a B.Sc. and M.Sc. in bioengineering from Ghent University and an Executive MBA from The Vlerick School of Management..

Van Hauwermeiren先生还担任iTeos Pharmaceuticals的董事会成员，并且在公司被百时美施贵宝收购之前曾担任RayzeBio的董事会成员。他拥有根特大学（Ghent University）生物工程理学学士和硕士学位，以及弗里克管理学院（Vlerick School of Management）的行政工商管理硕士学位。。

About Lexeo Therapeutics

关于Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs..

Lexeo Therapeutics是一家总部位于纽约市的临床阶段遗传医学公司，致力于通过应用开创性科学从根本上改变基因定义的心血管疾病和与APOE4相关的阿尔茨海默氏病的治疗方式来改变医疗保健。Lexeo采用逐步开发的方法，利用早期概念验证功能和生物标志物数据来推进心血管和APOE4相关阿尔茨海默病项目的管道。。

Media Response:

媒体回应：

Janine Bogris

Janine Bogris

(201) 245-6838

(201) 245-6838

janine.bogris@inizioevoke.com

janine.bogris@inizioevoke.com